There are more than 25,000 people in the US starting Wegovy each week.*
Avoid drastic increases in your Rx spend.
Have you reviewed your plan recently?
ProAct can help. Start the conversation:
Download ProAct's free GLP-1 medications report.
In 2022, Glucagon-like peptide-1 receptor agonist, or GLP-1 medications, took center stage in the discussion around the treatment of type 2 diabetes and weight loss and has only continued since.
*At least 25,000 people in the US are starting weight-loss drug Wegovy each week, drugmaker says
By Meg Tirrell, CNN
Thursday, May 2, 2024
Drugmaker Novo Nordisk said it’s been increasing supply of its sought-after weight-loss drug Wegovy, with at least 25,000 people now starting to take the medicine each week in the United States.
It’s about five times more than were able to start the medicine each week in December, the Danish pharmaceutical giant said in an earnings call Thursday.
“There is a very, very significant demand,” Novo Nordisk Chief Executive Officer Lars Fruergaard Jorgensen told CNN Thursday in an interview. “So for the foreseeable future, we believe the demand will outgrow supply. But we are gradually releasing more and more doses to the market.”
ProAct's free 2024 Drug Trend Report is now available.
Throughout our annual Drug Trend Report, we share both industry and ProAct specific information that helps validate our successes in achieving our mission to create and promote lasting partnerships built on value, transparency, and evidence-based pharmacy benefit management solutions.
More than just a PBM.
The world of pharmacy benefits is inherently complex – full of regulations and frequently changing laws and procedures. You need a partner who is willing and able to develop a long-term, high-touch relationship with you, so that the complexity of the changing prescription benefits environment doesn’t complicate your company’s individual needs. When you work with ProAct, you’ll be partnering with an employee-owned company with proven performance.